Friday, October 24, 2014

Tuesday Features

Stellar Biotechnologies harvests mollusks for KLH protein

Stellar Biotechnologies harvests mollusks for KLH protein

A mollusk living in the coastal waters off California from Monterey to the Baja Peninsula may hold the key to new therapies to treat cancer and autoimmune diseases. Frank Oakes Stellar Biotechnologies (OTCQB:SBOTF; TSX-V:KLH) has pioneered technology to grow the mollusk, known as the Giant Keyhole Limpet, and produce and purify KLH, or keyhole limpet... [Read more of this feature]


In conversation with Ron Babecoff

In conversation with Ron Babecoff

Ron Babecoff As a co-founder of BiondVax Pharmaceuticals (TASE:BNDX), Ron Babecoff has led the Israeli developer of a universal flu vaccine since its inception in 2003. Prior to BiondVax, Dr. Babecoff was with Omrix Biopharmaceuticals as marketing manager, where he was involved in identifying West Nile Fever treatments and building cooperation with... [Read more of this feature]


How Itamar Medical’s PAT signal is improving health

How Itamar Medical’s PAT signal is improving health

Using an unique and innovative technology known as peripheral arterial tone (PAT), Itamar Medical (TASE:ITMR) is detecting the functioning and health of arteries through a finger sensor for the diagnosis of sleep apnea and heart disease. Gilad Glick “Our technology is a non-invasive measurement of changes in a patient’s pulsatile arterial volume... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Stellar in KLH supply pact with Biovest

Stellar in KLH supply pact with Biovest

Stellar Biotechnologies (OTCQB:SBOTF; TSX-V:KLH) and Biovest International have executed a definitive supply agreement to meet Biovest’s requirements for Keyhole Limpet Hemocyanin (KLH) for use in its BiovaxID active immunotherapy to treat follicular non-Hodgkin’s lymphoma. BiovaxID combines autologous heterohybridoma-derived tumor idiotype... [Read more of this brief]


HCW starts Advaxis at buy

HCW starts Advaxis at buy

H.C. Wainwright has initiated coverage of Advaxis (NASDAQ:ADXS) with a “buy” rating and $8 price target. The stock closed at $2.84 on Wednesday. Advaxis’ strategy is to monetize a novel platform and to enter into partnerships to become a major player in the cancer immunotherapy market, writes analyst Swayampakula Ramakanth. The company’s... [Read more of this brief]


Nuvo sees $1-billion in peak yearly WF10 sales

Nuvo sees $1-billion in peak yearly WF10 sales

Nuvo Research (TSX:NRI) has released the results of a market study that forecasts its WF10 treatment could capture 10% to 15% of the U.S. refractory allergic rhinitis market with peak U.S. annual sales of $700-million to $1.1-billion. The study was preformed by Psscion Lifesciences Consulting to investigate the U.S. opportunity for WF10, an experimental... [Read more of this brief]


Novadaq inks Japan distribution deal with Mizuho Medical

Novadaq inks Japan distribution deal with Mizuho Medical

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has entered into an exclusive five-year agreement with Mizuho Medical for the distribution of its PINPOINT Endoscopic Fluorescence Imaging System in Japan. “The agreement with Mizuho Medical further strengthens our ability to achieve growth through our commitment to globalization,” Dr. Arun Menawat, president... [Read more of this brief]


Rosetta Genomics in pact for thyroid cancer diagnostic

Rosetta Genomics in pact for thyroid cancer diagnostic

Rosetta Genomics (NASDAQ:ROSG) has initiated a new public-private translational research project with the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool. The partnership was facilitated by... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+